Institutional investors hold a majority ownership of BIIB through the 94.07% of the outstanding shares that they control. This interest is also higher than at almost any other company in the Biotechnology industry. Last, during the quarter ended December 2013, these large investors purchased a net $389.5 thousand shares.
Mutual fund holders
Largest Quarterly Institutional Transactions
Latest Institutional Activity
T. ROWE PRICE ASSOCIATES, INC. Bought 823.9 Thousand shares of Biogen Idec Inc
DSM CAPITAL PARTNERS LLC Bought 720.4 Thousand shares of Biogen Idec Inc